Pacira Pharmaceuticals, Inc. (PCRX) Receives $49.08 Average PT from Analysts

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has earned a consensus recommendation of “Hold” from the twenty-one brokerages that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $49.38.

Several brokerages have weighed in on PCRX. Jefferies Group reissued a “buy” rating and issued a $59.00 price target on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. Zacks Investment Research raised Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Mizuho reissued a “buy” rating and issued a $53.00 price target (down previously from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. Needham & Company LLC began coverage on Pacira Pharmaceuticals in a report on Tuesday, August 22nd. They issued a “buy” rating and a $55.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $52.00 price target on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th.

In related news, CAO Kristen Marie Williams sold 10,000 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 23,455 shares in the company, valued at $938,200. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David M. Stack sold 58,885 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $38.34, for a total value of $2,257,650.90. Following the transaction, the chief executive officer now owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,735 shares of company stock valued at $2,692,594. Company insiders own 6.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. raised its position in Pacira Pharmaceuticals by 5.2% during the second quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock valued at $261,000 after acquiring an additional 270 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Pacira Pharmaceuticals by 9.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after acquiring an additional 302 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its position in Pacira Pharmaceuticals by 12.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock valued at $133,000 after acquiring an additional 303 shares in the last quarter. Denver Investment Advisors LLC grew its holdings in Pacira Pharmaceuticals by 6.8% in the second quarter. Denver Investment Advisors LLC now owns 6,850 shares of the company’s stock valued at $327,000 after purchasing an additional 435 shares during the period. Finally, Amalgamated Bank grew its holdings in Pacira Pharmaceuticals by 12.7% in the second quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock valued at $240,000 after purchasing an additional 566 shares during the period.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down $0.95 during mid-day trading on Thursday, reaching $45.25. The company had a trading volume of 711,636 shares, compared to its average volume of 923,928. Pacira Pharmaceuticals has a 12 month low of $29.81 and a 12 month high of $58.95. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.15. The business had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the company earned $0.20 earnings per share. equities analysts anticipate that Pacira Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.com-unik.info/2017/12/03/pacira-pharmaceuticals-inc-pcrx-receives-49-08-average-pt-from-analysts.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

What are top analysts saying about Pacira Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pacira Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit